In Table 1 , one of the contraindications to systemic estrogen therapy is a "known blood clotting disorder." Do you recommend screening for inherited thrombophilias before initiating hormone therapy in women? Is the risk profile different depending on the particular genetic clotting disorder and personal or family history of thrombosis? 
Response from Drs. Kaunitz and Manson: Question 5:
In regard to monitoring serum estradiol levels for women on transdermal estrogen, you mention a target range of 40-100 pg/mL. Given that serum levels fluctuate with oral estrogen therapy, do you ever recommend monitoring serum levels with this route? If so, when should blood be drawn in relation to the dosing schedule and what is the target range?
No, as we would not know how to interpret such levels.
Response from Drs. Kaunitz and Manson: Question 6:
In women utilizing estrogen therapy for vasomotor symptoms without a progestational agent and with an intact uterus, you mention the need for endometrial surveillance. How often do you recommend ultrasound monitoring and/or endometrial biopsy in this population?
Unfortunately, available data do not address this important question. One approach might be to monitor the endometrium every 6 months with vaginal ultrasonography. If the endometrial thickness is noted to exceed 5 mm, either adding progestin or performing an endometrial biopsy would be reasonable.
Question 7:
I receive multiple emails inviting me to learn laser vaginal rejuvenation for postmenopausal genitourinary syndrome. How does laser therapy help genitourinary syndrome of menopause? Is there any evidence to support laser rejuvenation therapy?
We have also heard about laser therapy for genitourinary syndrome of menopause. We are not aware of any controlled trial data that have evaluated this procedure.
